Metsera Inc. (NASDAQ: MTSR) issued a statement responding to litigation filed by Pfizer, characterizing the legal action as an attempt to acquire the company at a lower price than a competing offer from Novo Nordisk.

The company stated that Pfizer is "trying to litigate its way to buying Metsera for a lower price than Novo Nordisk." Metsera's board indicated it will continue to defend shareholders' interests and described Pfizer's litigation arguments as "nonsense" that will be addressed in court.

The statement reveals the existence of competing acquisition proposals involving Pfizer and Novo Nordisk, though specific financial terms were not disclosed. Metsera has filed proxy statements with the Securities and Exchange Commission related to a proposed transaction.

According to the company's disclosure, risks associated with Pfizer's proposed acquisition include litigation expenses, potential damages, and impacts on Metsera's stock price and business operations. The disclosure also mentions uncertainties regarding regulatory approvals and stockholder votes required to complete any acquisition.

The company noted that the litigation could affect Novo Nordisk's competing proposal. Metsera's definitive proxy statement has been distributed to stockholders in connection with the proposed transaction.

The statement was based on information contained in a press release issued by the company.